November 29, 2001
Planning for Bioterrorism
A preview of selected text from the upcoming book: “Physical and Biological Hazards of the Workplace, Second Edition”
By Peter H. Wald, MD and Gregg M. Stave, MD
Concerns about biological warfare and bioterrorism have existed for several decades, and have been heightened by the horrific events of September 11, 2001 , and their aftermath.
Several countries are known to have had biological warfare programs and stocks of agents are known to exist. At least 35 agents and organisms have been classified as possible bioterrorism concerns. The most widely discussed are anthrax, botulism, plague, tularemia, and smallpox (Table 20-5.). An epidemic of anthrax occurred in the former Soviet Union following an accidental release from a military facility in Sverdlovsk in 1979. As of this writing, in October 2001, there had been more than a dozen exposures to anthrax sent through the mail in the US , resulting in several cases of cutaneous anthrax and one fatality due to inhalation anthrax. These episodes have led to heightened fears about the possibility of further small and also large-scale bioterroism activities.
While publicized incidents of bioterrorism lead to significant fears, it should be kept in mind that the actual risk of being involved in an event is extremely small. The dissemination of large quantities of bioterroism agents and organisms fortunately has many significant technical challenges.
A prudent response to concerns involves different actions for individuals, professionals, and organizations. In general, people should be reassured that their personal risk is very low, and that they should take reasonable precautions in everyday life. This includes not handling suspicious looking mail and packages, and accessing their local emergency response system as needed. The practices of hoarding antibiotics or using antibiotics without a medical diagnosis should be discouraged.
For the medical and emergency response community, there is a need to learn to recognize the signs and symptoms of bioterrorism agents and organisms (Table 20-5.). This is of special concern because many of these diseases are otherwise uncommon, or, as in the case of smallpox, have not been seen for decades.
Significant improvements in the public health infrastructure are needed to enhance readiness for bioterrorism. Increased funding of these activities is likely in light of the events of 2001.
The animal care community also plays a role in surveillance, since some of the organisms involved are animal pathogens. Veterinarians, farmers, and others who work with and care for animals need to recognize potential public health implications of certain problems seen in animals.
Organizations and companies that handle mail and packages need to develop prudent handling procedures to recognize and isolate suspicious items. Medical, maintenance, safety, and security staffs, and emergency response personnel should receive appropriate training.
Finally, concerns about bioterrorism should be kept in perspective in the context of the everyday risks to life and health. Most preventable morbidity and mortality is due to addictions (especially tobacco) and modifiable lifestyle factors, and treatable diseases and risk factors. Individuals, healthcare personnel and health systems should maintain and increase the focus on these more mundane issues, as they will ultimately have the greatest impact on life and health.
Table 20-5. Potential Biological Warfare Agents
Disease |
Incubation |
Symptoms |
Signs |
Diagnostic tests |
Transmission and Precautions |
Treatment
(Adult dosage) |
Prophylaxis |
Inhaled Anthrax |
2-6 days
Range: 2 days to 8 weeks |
Flu-like symptoms
Respiratory distress |
Widened mediastinum on chest X-ray (from adenopathy)
Atypical pneumonia
Flu-like illness followed by abrupt onset of respiratory failure |
Gram stain (“boxcar” shape)
Gram positive bacilli in blood culture
ELISA for toxin antibodies to help confirm |
Aerosol inhalation
No person-to-person transmission
Standard precautions |
Mechanical ventilation
Antibiotic therapy
Ciprofloxacin 400 mg iv q 8-12 hr
Doxycycline 200 mg iv initial, then 100 mg iv q 8-12 hr
Penicillin 2 mil units iv q 2 hr
-- possibly add gentamicin |
Ciprofloxacin 500 mg po bid or doxycycline 100 mg po bid for ~ 8 weeks (shorter with anthrax vaccine)
FDA-approved vaccine: administer after exposure if available |
Botulism |
12-72 hours
Range:
2 hrs – 8 days |
Difficulty swallowing or speaking (symmetrical cranial neuropathies)
Symmetric descending weakness
Respiratory dysfunction
No sensory dysfunction
No fever |
Dilated or un-reactive pupils
Drooping eyelids (ptosis)
Double vision (diplopia)
Slurred speech (dysarthria)
Descending flaccid paralysis
Intact mental state |
Mouse bioassay in public health laboratories (5 – 7 days to conduct)
ELISA for toxin |
Aerosol inhalation
Food ingestion
No person-to-person transmission
Standard precautions |
Mechanical ventilation
Parenteral nutrition
Trivalent botulinum antitoxin available from State Health Departments and CDC |
Experimental vaccine has been used in laboratory workers |
Plague |
1-3 days by inhalation |
Sudden onset of fever, chills, headache, myalgia
Pneumonic: cough, chest pain, hemoptysis
Bubonic : painful lymph nodes |
Pneumonic: Hemoptysis;
radiographic pneumonia --
patchy, cavities, confluent consolidation
Bubonic: typically painful, enlarged lymph nodes in groin, axilla, and neck |
Gram negative coccobacilli and bacilli in sputum, blood, CSF, or bubo aspirates (bipolar, closed “safety pin” shape on Wright, Wayson's stains)
ELISA, DFA, PCR |
Person-to-person transmission in pneumonic forms
Droplet precautions until patient treated for at least three days |
Streptomycin 30 mg/kg/day in two divided doses x 10 days
Gentamicin 1-1.75 mg/kg iv/im q 8 hr
Tetracycline 2-4 g per day |
Asymptomatic contacts; or potentially exposed
Doxycycline 100 mg po q 12 hr x 7 days
Ciprofloxacin 500 mg po
Tetracycline 250 mg po q 6 hr x 7 days
Vaccine production discontinued |
Tularemia
“pneumonic” |
2-5 days
Range:
1-21 days |
Fever, cough, chest tightness, pleuritic pain
Hemoptysis rare |
Community-acquired, atypical pneumonia
Radiographic: bilateral patchy pneumonia with hilar adenopathy (pleural effusions like TB)
Diffuse, varied skin rash
May be rapidly fatal |
Gram negative bacilli in blood culture on BYCE (Legionella) cysteine- or S-H-enhanced media
Serologic testing to confirm: ELISA, microhemagglutination
DFA for sputum or local discharge |
Inhalation of agents
No person-to-person transmission but laboratory personnel at risk
Standard precautions |
Streptomycin 30 mg/kg/day IM divided bid for 10-14 days
Gentamicin 3-5 mg/kg/day iv in equal divided shoulders x 10-14 days
Ciprofloxacin possibly effective 400 mg iv q 12 hr (change to po after clinical improvement) x 10-14 days |
Ciprofloxacin 500 mg po q 12 hr x 2 wks
Doxycycline 100 mg po q 12 hr x 2 wks
Tetracycline 250 mg po q 6 hr
Experimental live vaccine |
Smallpox |
12-14 days
Range:7-17 days |
High fever and myalgia;
itching; abdominal pain; delirium
Rash on face, extremities, hands, feet; confused with chickenpox which has less uniform rash |
Maculopapular then vesicular rash -- first on extremities (face, arms, palms, soles, oral mucosa)
Rash is synchronous on various segments of the body |
Electron microscopy of pustule content
PCR
Public health lab for confirmation |
Person-to-person transmission
Airborne precautions
Negative pressure
Clothing and surface decontamination |
Supportive care
Vaccinate care givers |
Vaccination (vaccine available from CDC) |
Courtesy of Michael Hodgson, M.D., http://occenvmed.net/biocard16.doc , accessed 10/16/01
Bioterrorism Websites
http://www.bt.cdc.gov
http://www.hopkins-biodefense.org
http://biotech.law.umkc.edu/blaw/govdocs.htm
http://biotech.law.umkc.edu/blaw/Bioterror.htm
http://www.ama-assn.org/ama/pub/category/6206.html
http://www.usamriid.army.mil/education/bluebook.html
http://miemss.umaryland.edu/WMDSupplement.pdf
http://www.nbc-med.org
Exclusive Offer for WorkCare Users--Receive Free Shipping
Enter This Code 13911 in the "Product Search" Box of our publishing partner for Free
Shipping Charges on
“Physical and Biological Hazards of the Workplace, Second Edition”
by Peter H. Wald, MD and Gregg M. Stave, MD
NEW! Now extensively updated and expanded, this practical "how-to" reference provides an overview including basic information on either the physical type or underlying biology of workplace hazards. The new edition includes updated references and latest research. Biological agents are covered in equal depth, from the fundamentals of microbiology and infectious disease, to the specific details of organic hazards like wood dust and endotoxins. Release date, December 2001. Hardcover, 600 pages.
|